Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma
- 16 December 2002
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 17 (1) , 25-31
- https://doi.org/10.1016/s0268-960x(02)00059-0
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)Blood, 2002
- Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international studyBlood, 2002
- Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free SurvivalJournal of Clinical Oncology, 2002
- Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaSeminars in Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has FailedJournal of Clinical Oncology, 2002
- Diffuse large cell lymphomaCurrent Opinion in Oncology, 2001
- Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell LeukemiaNew England Journal of Medicine, 2001
- Chimeric Anti-CD20 (IDEC-C2B8) Monoclonal Antibody Sensitizes a B Cell Lymphoma Cell Line to Cell Killing by Cytotoxic DrugsCancer Biotherapy & Radiopharmaceuticals, 1997
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993